PhRMA Deal Remains Intact As Senate Majority Leaders Vote Against Drug Importation
This article was originally published in The Pink Sheet Daily
Executive Summary
The $80 billion deal the Rx industry struck as part of health care reform lives to see another day as drug importation fails on the Senate floor.
You may also be interested in...
Pharmaceuticals Not Likely To Be A Target Of Republicans In Coming Congress, Hill Watchers Say
Some issues - such as drug importation or rebates for Medicare/Medicaid dual eligibles - could surface. GOP could make "surgical strikes" on health reform law, including the Independent Payment Advisory Board, if overall repeal of reform law fails.
Pharmaceuticals Not Likely To Be A Target Of Republicans In Coming Congress, Hill Watchers Say
Some issues - such as drug importation or rebates for Medicare/Medicaid dual eligibles - could surface. GOP could make "surgical strikes" on health reform law, including the Independent Payment Advisory Board, if overall repeal of reform law fails.
A Look Ahead At The 2010 Election Cycle, In Brief
Sen. Dodd, instrumental in shaping Senate HELP bill, will not seek re-election: Sen. Chris Dodd, D-Conn., who played a major role in shaping the Senate Health, Education, Labor and Pensions Committee's health care reform bill, announced Jan. 5 he will not seek re-election to the Senate. Dodd took over the chairmanship of HELP in 2009 when the late Sen. Ted Kennedy fell ill. During his time in Congress, Dodd introduced a number of bills, including the Better Pharmaceuticals for Children Act, the Screening Abdominal Aortic Aneurysms Very Efficiently (SAAAVE) bill, the FDA Safety Act, the Fair Access to Clinical Trials Act, and the sunscreen monograph bill. He was a driving force in pushing for the creation of the Office of Patient Protection within FDA and helped to establish the Center for Postmarket Drug Evaluation. He also had a strong hand in regulating prescription drug DTC ads and spearheaded the pediatric exclusivity program